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ABSTRACT 
 
Starting from the lead structure we have identified in our previous works, we are 
extending our insight understanding of its potential inhibitory effect against both 
EGFR and HER2 receptors. Herein and using extended molecular dynamic 
simulations and different scoring techniques, we are providing plausible explanations 
for the observed inhibitory effect. Also, we are comparing the binding mechanism in 
addition to the dynamics of binding with two other approved inhibitors against EGFR 
(Lapatinib) and HER2 (SYR). Based on this information, we are also designing and in 
silico screening new potential inhibitors sharing the same scaffold of the lead 
structure. We have chosen the best scoring inhibitor for additional in silico 
investigation against both the wild-type and T790M mutant strain of EGFR. It seems 
that certain substitution pattern guarantees the binding to the conserved water 
molecule commonly observed with kinase crystal structures. Also, the new inhibitors 
seem to form a stable interaction with the mutant strain as a direct consequence of 
their enhanced ability to form additional interactions with binding site residues.  
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1. INTRODUCTION 
Kinases are known to be a viable target for anti-cancer drug development [1-4]. It’s 
estimated that around 30% of all drug design effort are dedicated for inhibition of 
kinases [5]. They are the second most important drug targets after GPCR’s (G Protein 
Coupled Receptors) [6].  Kinases are involved in many pathophysiological problems 
especially cancers where their over-expression can lead to certain types of malignant 
tumours [7,8]. Several kinase inhibitors are now in the market and many are under 
clinical trials. Resistance to current kinase inhibitors are emerging and wide-
spreading, so, there’s an urgent need for the development of more effective analogues 
that can tackle the problem of resistance [9]. In our two previous studies, we have 
presented a new series of a quinazoline based Lapatinib analogues with a potential 
anti-tumour activity and tested them against Epidermal Growth Factor Receptors and 
Human Epidermal growth factor Receptors 2 tyrosine kinases (EGFR/HER2) [10,11]. 
Indeed, several members of the new family showed micro-molar inhibitory activities 
and utilizing new binding patterns [10,11].  
It’s widely known that ligand binding to kinases is derived mainly by lipophilic vdW 
interactions [12,13]. In most cases, kinase inhibitors binds to the ATP binding pocket 
of the kinase domain of the enzyme, and they form several H-bonds with the 
backbone and side chains of the amino acids present in this region (Hinge region) 
[14]. Previous studies have shown that for these kinds of receptors including ligand 
induced polarization by protein environment may be important and ligand binding is 
best described by QM/MM docking [15,16]. Our previous results have also shown 
that the Lipophilic-vdW term may be the major factor that derives binding in this new 
series of inhibitors [10,11]. Other studies have also indicated that the electrostatic 
effect may be important in certain cases [3].  
The ligand-protein binding process is too complex to be described by a single 
representation of the ligand-protein complex produced as a result of the rigid receptor 
docking [17]. The various levels of approximations necessary to make docking rapid 
make scientists sceptical to really believe its results [18]. Proteins are not static idles, 
they are a very complex, moving and viable machines [19,20]. Introducing protein 
flexibility is increasingly important to describe the ligand-protein binding especially 
for targets known to be highly flexible such as kinases [21-23]. Kinases are known to 
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be a very challenging target for molecular modelling, particularly conventional 
docking. In our previous studies, we have utilized different docking and scoring 
methods to include some receptor flexibility [10,11]. These methods ranged from 
rigid docking with vdW radii scaling [17], induced fit docking (IFD) [24,25] and 
finally molecular dynamics (MD) simulations for some inhibitors against HER2 
receptor [10,11].  
In the current study, we are extending our insight understanding of the binding of the 
new series to their targets, EGFR and HER2 utilizing a much longer MD simulations. 
These kinds of studies are important as certain conformational changes are not 
accessible at the conventional MD time scale. We are also planning to use our 
existing knowledge from these simulations in order to design new powerful inhibitors 
that can inhibit EGFR/HER2 more efficiently. Another motivation is to design 
members that are less liable to the problem of resistance to current chemotherapeutic 
agents. As references, we are comparing the new series with the both originally co-
crystallized ligands, Lapatinib (EGFR) and SYR (HER2). Also, owing to the observed 
binding capability of the new series to interact with certain additional residues in the 
binding site, we are interested in analysing the interaction of the new series with some 
EGFR mutants, such as the famous T790M mutation [26,27]. This mutation, among 
others, is responsible for the development of resistance against Lapatinib as well as 
other Tyrosine Kinase Inhibitor’s (TKIs) [26,27]. Previous studies have shown that 
acquired Lapatinib resistance due to the T790M (gate keeper) mutation is mostly 
driven by either severe steric clashes or disruption of the H-bonding network due to 
the surrounding water molecules [28-30]. Moreover, the T790M mutation was linked 
to increased affinity to ATP and only those inhibitors having a covalent binding mode 
can still be effective [31].  
In the two previous studies, we have identified the inhibitor M19 and M20 to be the 
most active against EGFR and HER2 [10,11]. Herein, we are giving the results of a 
primary in silico screening of a designed compound library of 200 inhibitors. We will 
also represent one of the most promising members of the in silico screened compound 
library, which is the T9 inhibitor. Additionally, we will include SYR and Lapatinib as 
references for the simulation. We will also give some primary results for MD 
simulations of Lapatinib, M19 and T9 against the T790M EGFR mutant. In total, 9 
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complexes are subjected to long MD simulation; i. Lapatinib, M19 and T9 with wild 
type EGFR (WT), ii. Lapatinib, M19 and T9 with the T790M mutant EGFR(MUT) 
and iii. SYR, M19 and T9 with HER2 (WT). For simplicity, the wild type EGFR will 
be denoted as EGFR(WT) and the mutant strain will be denoted as EGFR(MUT). 
Wild type HER2 will be denoted as HER2. In addition to MD simulations, we have 
carried out binding free energy calculations based either on a single snapshot (Prime-
MM/GBSA) or ensemble of snapshots (AMBER-MM/PB(GB)SA). To account for 
the protein polarization effect, we have also rescored the relaxed MD complexes 
using QM/MM rescoring. 
 
2. METHODS AND COMPUTATIONAL DETAILS 
2.1. Design Rationale 
Figure 1 represents the 2D structure of Lapatinib, a dually acting anti-EGFR/HER2 
drug, SYR which is an HER2 inhibitor, in addition to the two leads that have been 
identified previously M19 and M20. We also include the 2D structure of the most 
active inhibitors of the new designed library identified in silico (T9). The in vitro 
measured IC50 of M19 is (1.935 µM: EGFR and 1.035 µM: HER2). The new 
designed inhibitors will benefit from the main skeleton of M19 in addition to 
substitution at four different sites where we believe that substitution may give rise to 
more effective inhibitors. At this stage, we decided not to go to severe modifications 
on the main nucleus itself to keep essential binding motifs.  
As we have identified previously, the binding of the new series to either EGFR or 
HER2 is very similar, the N1 atom of the quinazoline ring binds to Met793 (EGFR) 
or Met801 (HER2). The bulky 4-anilinoquinazoline side group binds to the side 
pocket formed by displacement of the Cα-helix. The two terminal tails at positions R1 
and R2 push the quinazoline ring for better filling of the hinge region and also form 
lipophilic interactions with the nearby residues [10,11]. 
Keeping in mind that the lipophilic vdW interaction terms is the most important term 
in these class of receptors, the primary focus on choosing different substituents is the 
halogen atoms at position R3 and R4 (-F, -Cl,-Br, -I, -CF3). For R1 and R2 positions, 
we increase the chain length from one carbon (-methoxy) to three carbons (-propoxy). 
We also utilize the erlotinib and Lapatinib side chain tails instead of the pure alkoxy 
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group substituents. The correctly docked inhibitors are given in supplementary data. 
Note that this list contains also modifications for the second most active anti-EGFR 
ligand identified previously which is M20.  
 
2.2. Docking and scoring calculations 
 
For more details about the docking preparation and setup, please refer to our previous 
work [11]. All ligands are docked against the EGFR crystal structure (PDB code: 
1xkk) using the same settings and ranked according to the XP_LipophilicEvdW term.  
Only inhibitors that satisfy the presence of a two predetermined H-bonds constraints 
(with Met793 and the conserved water molecule) are kept. The XP_LipophilicEvdW 
term was able to give the highest correlation with the experimentally measured 
inhibitory activity as we have shown previously (r(Pearson correlation)=0.78 and r2= 0.61) 
[10,11]. The designed T9 inhibitor has the highest XP_LipophilicEvdW score and is 
chosen for more detailed computational investigation. Our primary results suggest 
that T9 is able to form a more stable interaction with both EGFR and HER2. T9 is 
also much more able than M19 to retain the interactions with the conserved water 
molecules observed in several crystal structures of kinases complexed with their 
corresponding inhibitors [32-35]. The T9-HER2 complex is obtained by mutating the 
M19 inhibitor in the M19-HER2 complex obtained previously using the IFD protocol 
[10]. This is followed by a quick relaxation with Macromodel [36] to remove steric 
clashes.  
 
For those complexes that are subjected to the MD simulations, physics based 
rescoring is carried out applying both MM and QM/MM techniques. For MM 
rescoring, we apply a single, end point rescoring for the final trajectory snapshot 
produced from the MD simulations and using the Prime/MM-GBSA in the 
Schrodinger suite [37-39]. The complexes are also rescored applying the much more 
sophisticated AMBER/GB(PB)SA module in AMBER12 [40,41]. The 
AMBER/GB(PB)SA module takes the advantage of statistical averaging over many 
potential configurations. Every second frame of the produced 8000 frames has been 
chosen, i.e., a total of 4000 simulation snapshots have been utilized. For the QM/MM 
rescoring and because of the prohibitive computational expense, in DFT/MM 
rescoring we use only the ligand as the QM subsystem as implemented in the 
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QM/MM-PBSA script of Schrodinger and solvation effect is ignored in that case. The 
QM level is chosen to be the B3LYP/LACVP* level and the OPLS2005 force field is 
used to describe the MM subsystem.  For a more realistic QM/MM binding energy 
estimation, the AMBER QM/MM-GBSA calculations are utilized and the QM 
subsystem is extended to the ligand in addition to the surrounding residues within 5Å 
from the ligand. The dispersion corrected AM1 (AM1-D) [42,43] Hamiltonian is 
utilized for the QM subsystem and for the MM subsystem, the ff03 force field is used 
[44]. 
2.3. Molecular dynamic setup 
Nine inhibitor-protein complexes (see above) obtained from the previous rigid 
(EGFR) and IFD (HER2) runs are subjected to extensive molecular dynamic 
simulations. For the Lapatinib-EGFR (PDB code: 1XKK) and the SYR-HER2 (PDB 
code: 3PP0) complexes, the original crystal structures are used [45,46]. The structure 
preparation and the following MD simulations are performed using AMBER12 
software package [41] applying the ff03 force field  [44,47]. Single point calculations 
of the corresponding inhibitors are performed at the B3LYP/cc-pVTZ level of theory 
in ether (ε=4.2) solvent applying the IEF-PCM model [48] using the Gaussian 09 
program [49]. The inhibitor charges and other parameters are obtained using the 
RESP fitting  [50] procedures and  the general AMBER force field (GAFF) [51]. The 
complexes are then solvated with a box of TIP3P [52] water with a buffer size of 15Å 
and are neutralized by counter ions.  
 
Each system is then subjected to four consecutive minimization steps. In each step, 
water molecules and ions are allowed to move freely for a 1000 steps of steepest 
descent minimization followed by 4000 steps of conjugate gradient minimization. 
During minimization, protein and inhibitor atoms are constrained to their original 
positions by a force constant of 100 kcal·mol-1Å-2, then gradually releasing the force 
constraints to 50, 5 and zero (no constraints) kcal·mol-1Å-2, respectively. Following 
minimization, two consecutive steps of heating and equilibration are performed. First; 
each system is gradually heated in the NVT ensemble from 0°K to 300°K for 30 ps 
with a time step of 1 fs, applying a force constant of 10 kcal·mol-1Å-2 on the protein 
and inhibitor coordinates, and using Langevin dynamics with the collision frequency 
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γ of 1 ps-1 for temperature control. A further 1 ns simulation in the NPT ensemble is 
performed to equilibrate the system density applying a time step of 2 fs, which 
requires the use of SHAKE algorithm [53] to constrain all bonds involving hydrogen 
atoms. The temperature is controlled using Langevin dynamics with the collision 
frequency γ of 1 ps-1 and is kept at 300°K. The pressure is kept at 1 bar applying a 
Berendsen barostate with a pressure relaxation time of 1 ps. Each system is again 
relaxed in the NVT ensemble for another 2ns, in the first 1ns, heavy atoms are 
constrained by a force constant of 10 kcal·mol-1Å-2. Each system is then subjected to 
a 10 ns “warming up” simulation, followed by 4 production simulations of 20 ns long 
each i.e., 80(4*20) ns in total applying the NVT ensemble at 300°K and using  
Berendsen temperature control [54]. In all simulation steps, long-range electrostatics 
are computed using the particle mesh Ewald (PME) [55] with a non-bonded cut-off of 
12 Å. The edge effect is removed by applying periodic boundary conditions. All MD 
simulations are carried out using the PMEMD module of AMBER12 [41]. Binding 
energies are calculated from the MD trajectories using the PBSA module in 
AMBER12. 
 
3. RESULTS AND DISCUSSION 
 
Almost all TK inhibitors are either competitive or non-competitive inhibitors for the 
evolutionary conserved ATP binding site of the Tyrosine Kinase systems, EGFR and 
HER2. This ATP binding site is located in a deep cleft connecting the N-lobe and C-
lobe and is conventionally known as “Hinge region”. Owing to their high flexibility, 
available X-ray crystal structures of kinases complexed with their inhibitors show 
high degree of inhibitors diversity with respect to the molecular structure of the 
inhibitors. This high flexibility also imposes challenges to the molecular modelling 
process giving more room for the modelling scientist experience. There are several 
methods for TKIs classifications [56-58]. Briefly speaking, TKIs are classified into 
two main classes. The first class of inhibitors are those targeting either the active 
(DFG-in) or the inactive (DFG-out) state of the protein [45,59]. The second class of 
inhibitors are those bind to the (DFG-in) state in addition to a selectivity pocket 
formed as a result of large shift of the Cα-helix which also represents an inactive state 
of the protein [58]. This large shift creates a deep pocket in the back of the protein 
giving more room to accommodate bulky groups in the corresponding inhibitors. 
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Other inhibitors can also bind the ATP pocket and nearby allosteric sites [58]. An 
example from the first class is Gefitinib (Iressa®) which is able to bind the active 
(DFG-in) state of the protein [60,61]. This inhibitor, among others, is characterized 
by the presence of small side group at the 4-anilino site. An example of the second 
class is Lapatinib (Tykerb®) [62,63]. In the contrary of Gefitinib, Lapatinib possess a 
bulkier group at the 4-anilino site. This bulky group is accommodated by a deep 
pocket created as a result of a large shift of the Cα-helix [45,59]. The X-ray crystal 
structure of HER2 complexed with the inhibitors (SYR) has been released recently 
[64]. Previous modelling studies for HER2 have utilized homology modelling and 
using EGFR as a template owing to its high sequence similarity to HER2 (81%) 
[29,30].  
In general, inhibitor binding to either EGFR or HER2 is driven by strong lipophilic 
vdW forces in addition to strong H-bond with a conserved Met residue at the hinge 
region with the N1 atom of the quinazoline ring. Other studies have also identified the 
importance of the conserved water molecule typically seen in many crystal structures 
of kinases co-crystalized with their corresponding ligands. However, it’s an 
experimental fact that the binding energy contribution for this water molecule is 
essentially small and some of the active inhibitors previously reported lack the N 
atom at the 3 position (N3) that is responsible for the interaction with this water 
molecule [65,66]. In certain cases, an extra cyano group at this site reduces the need 
of this N3 atom via direct interaction with the nearby Thr [67,68]. For the new series 
under investigation, our primary results suggest that substitution of ring “C” by a 
halogen is essential to obtain such conserved water H-bond interaction, and this may 
be because of steric reasons.  
3.1. Docking and scoring 
Table 1 reports the XP_Gscore and the XP_LipophilicEvdW docking scores of the 10 
most active in silico designed inhibitors together with the substitution groups at R1, 
R2, R3 and R4. Previously, we have shown that the lead structure M19 was identified 
to be the top active inhibitor against both EGFR and HER2 [10,11]. For this section, 
we consider only EGFR as a result of data transferability which originates from high 
sequence similarity (81%). Our discussion is limited to the M19 modifications as 
M19 is the dually acting inhibitor whereas M20 shows a very weak anti-HER2 
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inhibitory effect (IC50 against EGFR: 2.582 µM and against HER2 99.96 µM) 
[10,11]. Given the exceptional power of the XP_LipophilicEvdW score to 
qualitatively identify the top active anti-EGFR as we have shown previously, we will 
mainly consider that score in the present docking study. The derivatives also appear 
in the table according to this score.  
As we can see in Table 1, all modifications indeed showed a higher 
XP_LipophilicEvdW score. Interestingly, pure alkoxy substituents at R1 and R2 
positions are more favoured than hetero substituted alkyl group, such as the ethoxy-
methoxy group present in Erlotinib (as in T8e with XP_LipophilicEvdW score of -
9.28 and T11e with XP_LipophilicEvdW score of -9.20) or the substituted Furyl 
group present in Lapatinib (as in T12l with an XP_LipophilicEvdW score of -8.96 ). 
We didn’t attempt to test electron withdrawing groups (EWG) at these two sites as 
previous studies have shown that EWG at these two sites of the anilinoquinazoline 
scaffold tend to decrease the anti-tumour activity significantly [69,70]. Also, it seems 
that optimal activity is achieved with Chlorination at R3 and R4 positions as the case 
in T9 (XP_LipophilicEvdW score of -9.40). Again, synthesis and biological 
investigation for this new series is warranted to build such solid conclusions.  
3.2. Molecular dynamic simulations 
3.2.1. General binding remarks 
Figure 2 represents the root mean square deviations plots (RMSDs) for the protein Cα 
atoms for the nine complexes under study through the 80 ns production simulations. 
As we can see in the figures, the inhibitors-protein complexes show an overall 
reasonable RMSD values and slight discrepancies are expected as a result of the 
known flexibility of kinases. As mentioned before, Lapatinib binds to the ATP 
binding site of either EGFR and/or HER2 receptors. The binding is driven mainly by 
vdW lipophilic interactions as have been shown before. An essential requirement for 
binding is the presence of a nitrogen atom at position no. 1 of the heterocyclic ring 
(N1). This heterocyclic ring may be a quinoline, quinazoline, pyridopyrimidine or 
even a mono-cyclic ring [71]. This nitrogen binds strongly to a Met residue at the 
hinge region (Met793 in EGFR and Met801 in HER2). Derivatives without N atom at 
this position are almost inactive [71,72]. Nitrogen substitution at position 3 (N3) 
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guarantees the binding to a water molecule seen frequently in kinase crystal 
structures. This water molecule forms a bridge between the N3 of the inhibitor and 
nearby residues side chains, such as Cys and Thr. It seems also that this water 
molecule, together with other water molecules, forms a network of H-bonds around 
the inhibitor, this site is referred to often as the S1 site. Although such water molecule 
is not essential for the anti-EGFR and/or anti-HER2 activity, recent studies link some 
binding problems against kinases to the disruption of such favouring interaction 
[12,30]. Another two potential sites for the presence of water molecules are the S2 
site in which water molecule bind to the aniline hydrogen, the third site S3 is linked 
to the nearby Gln amino acid. Figure 3 shows the potential locations of these three 
sites around the inhibitors under study. 
3.2.2. Water molecules occupancies 
Subsequent analysis of the MD trajectories shows that the H-bonds occupancies of 
these three sites are different for different inhibitors-protein complexes. Table 2 
represents the % occupancy of the potential water mediated H-bonds as a function of 
the simulation time. In all cases, an upper distance cut-off of 3.5 Å and a lower angle 
cut-off of 120° are used. Figure 3 displays potential water occupancy sites (S1, S2 
and S3) among the studied inhibitors. As there’s a possibility for the two hydrogens 
of the same water molecule or more than one water molecule to interact 
simultaneously, one may expect that the occupancy may be even more than 100%.  
In all situations, the most conserved occupancy is observed with the S3 site.  The T9-
HER2 complex achieves the highest value of 123.54% of the simulation time for this 
site (S3). We should stress here that neither of these water molecules have been got 
from the original crystal structure nor constrained to their 3D coordinates. However, 
as the occupant water molecules at this site (S3) don’t directly interact with the 
inhibitor, this site may have the least influence among the three observed water sites. 
For S2 site, %occupancy values for all complexes are comparable with the exception 
of the SYR-HER2(WT) complex of having Zero% occupancy at this site possibly 
because of the potential formation of an intramolecular H-bond.  
The most interesting water %occupancy is observed with the S1 site.  The highest 
occupancies are achieved with either SYR-HER2(WT) with a %occupancy of 97.54 
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followed by Lapa-EGFR(WT) with a value of  94.50. For the new inhibitors, both the 
lead (M19) and the optimized structure (T9) show an interesting behaviour. M19 
seems to completely lack such interaction in all situations with a maximum value of 
1.71% for its complex with EGFR(WT). Such low occupancy value can be 
considered essentially insignificant. In contrast to M19, T9 seems to have a much 
higher occupancy at the S1 site of about 91.05% with HER2(WT) and a value of 
70.03% with EGFR(WT). As expected and as a result of the increased hydrophobicity 
around the S1 site due to the T790M mutation, water occupancy at this site is 
significantly reduced from 94.50% in Lapa-EGFR(WT) to 28.69% in Lapa-
EGFR(MUT) and from 70.03% in T9-EGFR(WT) to Zero% in T9-EGFR(MUT). A 
quick look on the literature show that “almost” all effective anilinoquinazoilne EGFR 
and/or HER2 competitive inhibitors, particularly the currently marketed inhibitors, 
are substituted at ring “C” mostly with an electron withdrawing groups, such as 
halogen and/or ethyne groups [66,69,73].  In the new series, the lead structure M19 
doesn’t have but the modified one T9 does have such substitution, so, T9 possess 
such water mediated interaction at S1 as we showed before. Our primary 
investigation showed that this may be because of steric reasons.  Because of the 
existence of different rotomeric conformations of the side chains of nearby residues 
responsible for binding to this bridging water molecule at the S1 site, i.e. Thr790 and 
Thr854, such interaction is possible in Lapatinib and T9 but not possible in M19.  The 
same is true for inhibitors-HER2 complexes and the differences between rotomeric 
structures of Thr798 and Thr862 are responsible for the existence of high water 
occupancy at the S1 site for SYR (97.54%) and T9 (91.05%) but as low as 0.11% for 
M19.  
3.2.3. Binding to the conventional hinge residues 
As mentioned before, inhibitor binding to both EGFR and HER2 is driven mainly by 
lipophilic vdW interactions. The strength of this binding can be in silico assessed by 
calculating the energy of binding as well as the stability of the formed complexes. For 
the inhibitors under study, all are able to form a stable interaction with the conserved 
hinge Met residue (Met793 for EGFR and Met801 for HER2). Previous studies have 
shown that for EGFR receptors, acquired resistance due to the T790M mutation 
prevents stable interaction with competitive inhibitors, including Lapatinib. This has 
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been previously proposed to be attributed to several reasons; (i) steric clashes, (ii) 
increased sensitivity to ATP and (iii) disruption of the surrounding waters mediated 
H-bonds [29,30]. Indeed, we show that the surrounding water mediated H-bonds 
network is severely disrupted in case of the T790M mutation. However, we believe 
that such disruption is not enough alone to explain the huge reduction in the ability of 
Lapatinib to inhibit EGFR as a consequence of this mutation. The anti-tumour 
activity of Lapatinib against EGFR is severely decreased going from the EGFR(WT) 
with an IC50 of 0.022 µM to EGFR(MUT) with an IC50 of  3.3 µM [29]. We believe 
that a combination of the aforementioned explanations is the most likely reason.    
Figure 4 shows the fluctuation of the N1-Met793 (EGFR) or the N1-Met801 (HER2) 
during the 80 ns simulation time. This H-bond is the most important anchor and, as 
we mentioned before, inhibitors lack such H-bond are inactive. Indeed, in all cases 
the fluctuation is minimal and this H-bond can be considered very stable. An 
exception is the Lapatinib complex with the EGFR(MUT) that shows a large 
fluctuation after about 60 ns to about 5 Å. This may shed some light on the possible 
instability of Lapatinib-EGFR(MUT) complex. However, ligand escape during the 
conventional simulation time for EGFR(MUT) is not expected giving the limitations 
of the current modelling tools and the complicated energy landscape [74]. This has 
been previously discussed for the EGFR T790M mutant binding to Gefitinib [74]. In 
all other complexes, the average value of this H-bond ranges between 2-2.5 Å.  
3.2.4. Binding to the additional hinge residues 
Previously we have demonstrated the ability of the new inhibitors to bind to 
additional hinge residues in both EGFR and HER2 binding sites, and due to the high 
sequence similarity between both receptors, the locations of such interactions are 
similar [10,11]. In general, the most important interactions are the two charge assisted 
H-bonds formed with Asp855 and Lys745 (EGFR) or Asp863 and Lys753 (HER2) 
and mediated by the N-H group of ring “D” and the extra imino group on the same 
ring, respectively. Because of structural reasons, neither SYR nor Lapatinib are able 
to form such charge assisted interactions. However, another possibility for SYR 
interaction with Asp863 is via the terminal hydroxy group at the other side of the 
molecule. This interaction is indeed observed in the crystal structure itself and is 
formed during the simulation. Figure 5 displays the interaction of T9 and M19 with 
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the three receptor types (EGFR(WT), EGFR(MUT) and HER2). As such static 
representation may be misleading as it doesn’t provide any dynamic information, 
Table 3 reports the %occupancies of such interaction as a function of the simulation 
time. As we can see in the table, the most stable interactions are the T9-
Asp863(HER2) and the M19-Lys753(HER2) interactions with an occupancy of 
71.03% and 66.86%, respectively. T9 seems to keep a higher %occupancy for these 
two interactions with EGFR(MUT) than its corresponding interaction with 
EGFR(WT). Also, the occupancy of the M19 interaction with Lys745-EGFR(MUT) 
is given by 66.2% whereas its interaction with Lys745-EGFR(WT) is given by 
41.96%. In contrast to the M19 interaction with Lys745 which is higher in the 
EGFR(MUT) than the EGFR(WT), the occupancy of M19 H-bond interaction with 
Asp855 is higher in the EGFR(WT) (12.51%) than with EGFR(MUT) (1.78%). 
Occasionally, M19 is able to form an H-bond with the amide oxygen of Asp863 in 
HER2. 
This demonstrated ability of the new inhibitors to bind to these extra residues is a 
good point that may favour their future development. It’s known that some of the 
very challenging mutations that result in resistance to current EGFR/HER2 are those 
present in the vicinity of the hinge region. An example of such mutations is the 
stubborn T790M mutation which is known to be present in more than 50% of all 
patients whose tumours showed an acquired resistance for TKIs [75,76]. Formation of 
very strong interactions with additional residues may retain the antitumor activity 
even in the EGFR/HER2 resistant strains including the T790M mutation. Although it 
has been shown that irreversible inhibitors may be the agents of choice for the 
resistant strains, toxicity concerns may be a problem for these agents [28,77,78].  
3.3. Binding energy calculations 
3.3.1. Total binding energy 
Table 4 reports the binding energy scores for the compounds under study at different 
levels of QM/MM and pure-MM levels of theory. In general, MM based methods 
perform well in comparison with the QM/MM based methods. With the exception of 
the pure gas phase ∆E QM/MM binding energy scores, T9 exhibits higher binding 
energy scores than M19 in all situations. We believe that this rather questionably high 
∆E QM/MM binding energy score for M19 (-141.54 kcal·mol-1Å-2) is a direct 
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consequence for the absence of the solvent screening effect and the statistical 
inaccuracies as well. The absence of such screening effect amplifies certain 
intermolecular interactions significantly. However, further investigation is required to 
identify the origin of such exaggerated score. The introduction of the conserved water 
molecule seems to show some increase to the overall binding score and particularly to 
the ∆Ecol term as we will discuss in the following section. Direct comparison between 
binding energy scores for ligands having different scaffolds should be conducted with 
caution as a result of different entropic terms and dissociation rates.   
 
Overall, Lapatinib shows a higher binding energy scores for the mutant (MUT) rather 
than the wild-type (WT) strain of EGFR. Admittedly enough, only the dispersion 
corrected AM1 Hamiltonian (AM1-D) predicts M19 to be a better binder for HER2 (-
162.85 kcal·mol-1) than EGFR (-133.60 kcal·mol-1). This is consistent with 
experimentally measured IC50 for M19 against HER2 (1.035 µM) and EGFR (1.935 
µM) [10,11]. Also, we tried to include all surrounding residues within the binding site 
in the QM region as no much QM accuracy is expected to be gained considering only 
the ligand as the QM subsystem.  Other binding energy scores show discrepancies as 
a result of different modelling techniques and theory levels.    
 
3.3.2. Component contribution to total binding energy 
 
Table 5 reports the individual binding energy components calculated using the 
AMBER/MM-PBSA tool. The total binding energy mentioned in that table (∆Etot) 
doesn’t include the desolvation penalties included in Table 4, i.e., we can consider 
that ∆Etot is a “gas phase” binding energy. As we can see in the table and in all 
complexes, the ∆EvdW term is the major component. For the EGFR(WT) complexes, 
T9 shows enhanced both ∆EvdW and ∆Ecol binding energy components (-83.09 
kcal·mol-1 and -31.57 kcal·mol-1, respectively) with respect to that for M19 (-75.99 
kcal·mol-1 and -24.20 kcal·mol-1, respectively) and Lapatinib (-76.42 kcal·mol-1 and -
29.16 kcal·mol-1, respectively). Interestingly, including the conserved water molecule 
(S1) through the 1WAT protocols enhances the ∆Ecol term, with little or no effect on 
the ∆EvdW term. This results in an increase in the ∆Ecol term by 3.49 kcal·mol-1 and 
4.22 kcal·mol-1 for both T9 and Lapatinib, respectively. 
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For the EGFR(MUT) complexes, we notice an increase in both the ∆EvdW and ∆Ecol 
terms for Lpatininib (-85.88 kcal·mol-1 and -39.15 kcal·mol-1, respectively) with 
respect to that for T9 (-81.23 kcal·mol-1 and -26.46 kcal·mol-1, respectively) and M19 
(-73.27 kcal·mol-1 and -22.27 kcal·mol-1, respectively). The Lapatinib binding energy 
components in the EGFR(MUT) seem to be even higher than their corresponding 
values for the EGFR(WT). Such behaviour has been pointed out previously by Huang 
et al. [30].  
 
For the HER2 complexes, T9 seems to have the highest contribution from the ∆EvdW 
term which is given by -76.19 kcal·mol-1 compared to M19 (-70.56 kcal·mol-1) or 
SYR(-68.27 kcal·mol-1). The ∆Ecol term for SYR seems to be greatly enhanced by the 
introduction of the water molecule (∆∆Ecol = 5.4 kcal·mol-1), in contrast to that gain 
for T9 (∆∆Ecol = 3.4 kcal·mol-1).  
3.3.3. Per-residue binding energy decomposition 
Individual binding energy components on per-residue decomposition analysis are also 
shown in Figure 6. We choose only the most important residues to show. Choice is 
based primarily on the residue contribution to the ∆EvdW term for the new inhibitors, 
T9 and M19. Figure labels represent the exact binding contribution of each selected 
amino acid to the corresponding term. As we can see in the figure, both Asp855(863) 
and Lys745(753) have a high contribution to the binding energy for both the ∆EvdW 
and ∆Ecol terms. Also, in all complexes, T9 got the highest contribution from 
Met793(801) which can be considered the most important anchoring point.  
 
For the EGFR(WT) complexes, the Asp855 contribution for the ∆EvdW term is higher 
for M19 (-3.48 kcal·mol-1) than for T9 (-3.35 kcal·mol-1), on the other hand, the 
Lys745 contribution is higher for T9(-2.28 kcal·mol-1) than for M19 (-1.27 kcal·mol-
1). Discrepancies between T9 and M19 for the ∆Ecol term regarding these two amino 
acid residues seem to be non-specific in nature as they are not directly correlated with 
the H-bond occupancies (Table 3). Other possibility may be because of the nature of 
the involved H-bond itself. What makes the first assumption more acceptable is the 
slightly high ∆Ecol contribution of Asp855 residues to Lapatinib binding although 
Lapatinib doesn’t form a direct specific H-bond interaction with this residue. The 
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Asp855 contribution to the ∆Ecol term for Lapatinib binding to the EGFR(MUT) is 
given by -7.16 kcal·mol-1, again there’s no direct specific H-bond interaction between 
Lapatinib and Asp855. Also, for the EGFR(MUT), T9 and M19 possess a higher 
contribution from Asp855 to the ∆EvdW term (-2.52 kcal·mol-1and -3.63 kcal·mol-1, 
respectively) than Lapatinib (-2.1 kcal·mol-1).  
 
For HER2 complexes, it seems that M19 get the highest contribution for the ∆EvdW 
from the Phe864 residue (-3.06 kcal·mol-1). This residue is particularly interesting as 
neither SYR nor Lapatinib (it’s the Phe856 in EGFR) show a significant contribution 
to the overall ∆EvdW term from this residue. Indeed, the good contribution for this 
residue to the ∆EvdW term comes as a consequence of the additional aromatic ring in 
both T9 and M19. Future development to this series will include this residue as an 
important target. For the ∆EvdW term, it seems that M19 gets a higher contribution 
from the Asp863 residue (-2.35 kcal·mol-1) than T9 (-1.97 kcal·mol-1), however, T9 
got a higher contribution from Lys753 (-2.03 kcal·mol-1) than M19(-0.94 kcal·mol-1) 
for the same term. For the ∆Ecol term, M19 shows higher contributions from both 
Asp863 (-4.45 kcal·mol-1) and Lys753 (-5.94 kcal·mol-1) than T9 (-3.03 kcal·mol-1 
and -5.2 kcal·mol-1 , respectively).  
 
Now this question arises, do we expect the in silico designed dually acting inhibitor 
(T9) to be of a better inhibitory profile than Lapatinib. This question is not easy to 
answer given the limitations of the currently available modelling tools. Assessment of 
the ligand-protein binding requires more than just the binding energy scores. For 
example, previous studies have shown that although Gefitinib may possess a higher in 
silico binding energy than lapatinib against EGFR, the Lapatinib-EGFR complex is 
much more stable [58]. Lapatinib forms an “almost” irreversible complex with EGFR 
with a t1/2 of about 224 minutes [29]. Further development, synthesis and biological 
testing are warranted in order to achieve the best outcome. 
 
4. CONCLUSIONS 
 
In this study, we have characterized the binding modes and exact mechanisms of 
inhibition of a recently synthesized 4-anilinoquinazoline series against both wild type 
and T790 mutant EGFR in addition to wild type HER2. It seems that substitution at 
ring “C” is essential to achieve optimum interaction with the conserved water 
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molecule observed frequently in kinase crystal structures. The new series also 
demonstrated an ability to bind additional residues in the binding site utilizing direct 
H-bonding interactions, namely; Asp855 and Lys745 for EGFR and Asp863 and 
Lys753 for HER2. Inclusion of the binding site water in calculating the total binding 
energy resulted in an increase of about 3-5 kcal·mol-1 and this enhancement was 
mainly due to increase in the ∆Ecol term. Both MM and QM/MM based rescoring 
methods perform well in predicting the overall trends in binding energy. 
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Table 1: R group modifications of the in silico designed compound library with the docking scores. 
  
 
a At 5 µM concentration. 
Title Substituents XP GScore XP_LipophilicEvdW %inhibition a IC50 (µM) 
 R1 R2 R3 R4     
T9 -(CH2)2-CH3 -(CH2)2-CH3 -Cl -Cl -9.02 -9.40   
T16 -(CH2)2-CH3 -(CH2)2-CH3 -Cl -CF3 -8.88 -9.39   
T11 -(CH2)2-CH3 -(CH2)2-CH3 -Br -Br -8.89 -9.38   
T1 -(CH2)2-CH3 -(CH2)2-CH3 -Cl -Br -8.92 -9.33   
T8e -(CH2)2-O-CH3 -(CH2)2-O-CH3 -Br -Cl -8.62 -9.28   
T11e -(CH2)2-O-CH3 -(CH2)2-O-CH3 -Br -Br -8.74 -9.20   
T12 -(CH2)2-CH3 -(CH2)2-CH3 -F -Br -10.05 -9.20   
T3 -(CH2)2-CH3 -(CH2)2-CH3 -Cl -F -9.03 -9.18   
T8 -(CH2)2-CH3 -(CH2)2-CH3 -Br -Cl -11.33 -8.99   
T12l 
O
NH
S O
O
 
-H -F -Br -7.76 -8.96   
M19 -CH3 -CH3 -H -Br -10.78 -8.40 72 1.935 
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Table 2: %Hydrogen-bond occupancy analysis of the three observed water sites as a 
function of the simulation time
Inhibitor-EGFR(WT) Inhibitor-EGFR(MUT) Inhibitor-HER2(WT) 
T9  S1 70.03 T9 S1 Zero T9 S1 91.05 
S2 85.54 S2 70.09 S2 67.44 
S3 89.89 S3 91.80 S3 123.54 
M19 
 
 
S1 1.71 M19 
 
 
S1 1.10 M19 
 
 
S1 0.11 
S2 41.61 S2 69.25 S2 58.20 
S3 61.09 S3 78.14 S3 111.48 
Lapa 
 
 
S1 94.50 Lapa 
 
 
S1 28.69 SYR 
 
 
S1 97.54 
S2 94.77 S2 60.84 S2 Zero 
S3 114.90 S3 69.14 S3 113.65 
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Table 3: %Hydrogen-bond occupancy analysis of the additional potential hinge 
residues interaction. 
Inhibitor-EGFR(WT) Inhibitor-EGFR(MUT) Inhibitor-HER2(WT) 
T9  Asp855 14.49 T9 Asp855 66.51 T9 Asp863 71.03 
 
 
Lys745 13.02  Lys745 31.84  Lys753 56.92 
M19 Asp855 12.51 M19 Asp855 1.78 M19 Asp863 Zero 
 Lys745 41.96  Lys745 66.2  Lys753 66.86 
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Table 4: Experimental %inhibition together with simulated binding energies and scores for the MD produced complexes (kcal·mol-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Calculations are carried out using the QM/MM-PBSA script from Schrödinger and ignoring solvation, the B3LYP/LACVP* //OPLS2005 level 
of theory is applied, QM substructure composed of inhibitor atoms only.  
b
 QM system composed of ligand and the nearby residues within 5 Å, QM system was treated at the dispersion corrected AM1 Hamiltonian 
(AM1-D) and MM system was treated at the AMBER-ff03 force field.   
c
 Residues within 6 Å of the inhibitor are treated flexibly. 
d
 Values between brackets are those obtained upon inclusion of the conserved water molecule in the calculation. 
e See Ref. [10,11]. 
f At 5 µM concentration, See Ref. [10,11]. 
g See Ref. [29]. 
 
Title ∆E QM/MM a  AMBER-QM-
MM/GBSA b   
Prime-
MM/GBSA c  
AMBER-
MM/GBSA d 
AMBER-
MM/PBSA d  
IC50 (µM)e %inhibitionf  
EGFR(WT)        
M19 -141.54 -133.60 -136.14 -65.63 -95.29 1.935 72 
T9 -97.71 -139.86 -152.83 -69.95  (-73.58) -103.44  (-108.46)   
Lapatinib -116.86 -91.16 -128.37 -68.12  (-71.74) -99.93    (-103.57) 0.022  
        
EGFR(MUT)        
M19 -84.25 -121.18 -130.75 -61.83 -92.18   
T9 -115.27 -139.06 -153.56 -70.45 -102.07   
Lapatinib -118.44 -96.38 -142.36 -75.16 -105.62 >3.3g  
        
HER2        
M19 -86.33 -162.85 -116.14 -59.34 -93.34 1.035 85 
T9 -104.36 -164.23 -159.58 -66.28  (-69.04) -100.38   (-104.36)   
SYR -107.75 -77.73 -136.64 -62.38  (-66.31) -91.36     (-96.02) 0.011  
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Table 5: Decomposed binding energies of the MD studied complexes (kcal·mol-1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 Values between brackets are those obtained upon inclusion of the conserved water 
molecule in the calculation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Title ∆EvdW a ∆Ecol a ∆Etot(vdW+col) a 
EGFR(WT)    
M19 -75.99 -24.20 -100.19 
T9 -83.09(-84.07) -31.57(-35.06) -114.66(-119.13) 
Lapatinib -76.42(-77.15) -29.16(-33.38) -105.58(-110.53) 
    
EGFR(MUT)    
M19 -73.27 -22.27 -95.54 
T9 -81.23 -26.46 -107.69 
Lapatinib -85.88 -39.15 -125.03 
    
HER2    
M19 -70.56 -26.75 -97.31 
T9 -76.19(-76.96) -20.23(-23.63) -96.42(-100.59) 
SYR -68.27(-68.69) -24.59(-29.99) -92.86(-98.68) 
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Figure captions 
 
 
Figure 1: The 2D chemical structures of the compounds under study. 
 
Figure 2: Cα backbone atoms RMSDs plots for the studied complex during the 80 ns 
MD simulations. 
 
Figure 3: Potential binding poses and water orientations of the studied complexes. 
 
Figure 4: Hydrogen bond distance profiles between the inhibitors and the Met hinge 
residue (Met793 in EGFR and Met801 in HER2) during 80 ns MD simulation. 
 
Figure 5: 3D interaction with the conserved hinge region Met residue and the 
additional residues Asp and Lys. 
 
Figure 6: Per-residue binding energy decomposition of the 9 MD runs using the 
MMPBSA module of AMBER. 
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Figure 1: The 2D chemical structures of the compounds under study. 
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Figure 2: Cα backbone atoms RMSDs plots for the studied complex during the 80 ns MD simulations. 
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Figure 3: Potential binding poses and water orientation of the 9 studied complexes. 
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Figure 4: Hydrogen bond distance profiles between the inhibitors and the Met hinge residue (Met793 in EGFR and Met801 in HER2) during 80 ns 
MD simulation.   
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Figure 5: 3D interaction with the conserved hinge region Met residue and the additional residues Asp and Lys.  
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Figure 6: Per-residue binding energy decomposition of the 9 MD runs using the MMPBSA module of AMBER
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